Rigel Pharmaceuticals Welcomes Dr. Mark W. Frohlich to Board
Rigel Pharmaceuticals Welcomes Dr. Mark W. Frohlich to Board of Directors
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) recently announced the exciting appointment of Dr. Mark W. Frohlich to its Board of Directors. With over 25 years of experience in the field of oncology, Dr. Frohlich brings a wealth of knowledge and expertise in developing groundbreaking cellular immunotherapies for cancer treatment.
Raul Rodriguez, president and CEO of Rigel, expressed enthusiasm for Dr. Frohlich's addition to the team. "We are pleased to have Mark join our Board. His extensive background in clinical development and portfolio strategy will be invaluable as we advance our hematology and oncology pipeline," stated Rodriguez.
Currently, Dr. Frohlich holds the position of chief executive officer at Indapta Therapeutics, a biotechnology firm dedicated to creating allogenic natural killer cell therapies aimed at addressing the unmet medical needs of cancer patients and those with autoimmune conditions. His previous roles include serving as a strategic advisor for various immuno-oncology companies, which showcases his versatility and deep understanding of the field.
Prior to his tenure at Indapta, he significantly impacted Juno Therapeutics, where he was instrumental in the development of the FDA-approved CAR T-cell therapy, Breyanzi, for large B-cell lymphoma. His contributions to Juno Therapeutics continued until its acquisition by Celgene, which is now part of Bristol Myers Squibb.
Dr. Frohlich played a pivotal role at Dendreon Corporation, known for pioneering cellular immunotherapy. As the chief medical officer and executive vice president of Research & Development, he oversaw the clinical team responsible for bringing PROVENGE, one of the first approved cancer immunotherapies, to market.
Before his corporate endeavors, Dr. Frohlich was an assistant adjunct professor of hematology/oncology at the University of California, San Francisco (UCSF). His specialization in urologic oncology allowed him to conduct laboratory and clinical research that has driven advancements in cancer treatment methodologies.
Dr. Frohlich's academic achievements are equally impressive, having earned a Bachelor of Science in Electrical Engineering and Economics from Yale College, alongside an M.D. from Harvard Medical School. His academic prowess was further highlighted by his completion of a fellowship in hematology/oncology at UCSF and serving as chief resident in medicine there.
Reflecting on his new role, Dr. Frohlich noted, "I am excited to join Rigel as it continues to advance its development pipeline. I believe the IRAK1/4 and IDH1 inhibitor programs possess significant potential to benefit patients with lower-risk myelodysplastic syndrome and glioma, respectively. I look forward to collaborating with the team to bring these innovative therapies to patients who are in need of new treatment options."
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a dedicated biotechnology company focused on discovering and developing novel therapies that markedly improve the lives of patients facing hematologic disorders and cancer. Established in 1996, the company is headquartered in South San Francisco, California. More information about Rigel and its pipeline can be found on their website, www.rigel.com.
Contact for Investors & Media
Investors
For investor inquiries, please contact:
Rigel Pharmaceuticals, Inc.
Phone: 650.624.1232
Media
For media inquiries, contact:
David Rosen
Argot Partners
Phone: 646.461.6387
Frequently Asked Questions
Who is Dr. Mark W. Frohlich?
Dr. Mark W. Frohlich is a seasoned medical oncologist with over 25 years of experience in developing cancer therapies and has recently been appointed to Rigel's Board of Directors.
What is Rigel Pharmaceuticals known for?
Rigel Pharmaceuticals focuses on discovering and developing innovative therapies for hematologic disorders and cancer.
What role did Dr. Frohlich hold before joining Rigel?
Before joining Rigel, Dr. Frohlich served as the CEO of Indapta Therapeutics, focusing on allogenic natural killer cell therapies.
What are some key products developed by Rigel?
Rigel's portfolio includes novel therapies for various hematologic disorders and cancer treatment approaches.
How can I learn more about Rigel's products?
For more information on Rigel's marketed products and development pipeline, visit their official website at www.rigel.com.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.